Literature DB >> 2906320

How to examine patients using the Abnormal Involuntary Movement Scale.

M R Munetz1, S Benjamin.   

Abstract

The Abnormal Involuntary Movement Scale (AIMS) examination has been widely recommended for periodic screening for tardive dyskinesia and follow-up of patients diagnosed with the disorder. However, few guidelines exist about how to use the examination in clinical practice. The authors discuss for whom, when, and how the AIMS examination can be used in a multidisciplinary setting; amplify the original instructions for the examination; and propose conventions to clarify scoring. Noting that the AIMS examination is not specific for tardive dyskinesia, they discuss a clinical approach to the patient who is found to have abnormal movements. The AIMS examination is best conducted within the context of an ongoing treatment program, the authors say, and should be part of the informed consent process necessary with patients treated with neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906320     DOI: 10.1176/ps.39.11.1172

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  59 in total

1.  Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Authors:  Gaurav Jain
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review.

Authors:  Seema Jain; Rebecca Andridge; Jessica A Hellings
Journal:  J Autism Dev Disord       Date:  2016-04

3.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

Review 4.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

Review 5.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  The appropriateness of routine medication treatment for schizophrenia.

Authors:  Alexander S Young; Noosha Niv; Amy N Cohen; Christopher Kessler; Kirk McNagny
Journal:  Schizophr Bull       Date:  2008-11-07       Impact factor: 9.306

7.  Effectiveness evaluation of a pharmacist-driven monitoring database for tardive dyskinesia.

Authors:  Lauren A Diefenderfer; Leigh Anne Nelson; Ellie Elliott; Yifei Liu; Courtney Iuppa; Elizabeth Winans; Roger W Sommi
Journal:  Hosp Pharm       Date:  2014-06

8.  Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.

Authors:  Andrea Aguglia; Ludovico Mineo; Alessandro Rodolico; Maria S Signorelli; Eugenio Aguglia
Journal:  Int Clin Psychopharmacol       Date:  2018-05       Impact factor: 1.659

9.  The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.

Authors:  Joshua A Lile; William W Stoops; Lon R Hays; Craig R Rush
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

10.  High-resolution tracking of motor disorders in Parkinson's disease during unconstrained activity.

Authors:  Serge H Roy; Bryan T Cole; L Don Gilmore; Carlo J De Luca; Cathi A Thomas; Marie M Saint-Hilaire; S Hamid Nawab
Journal:  Mov Disord       Date:  2013-03-20       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.